SABCS 2024
Read the full Report (pdf)
San Antonio Breast Cancer Symposium 10–13 December 2024 San Antonio, TX, USA
Featured articles
Meet the Trialist: Prof. Hope Rugo on the P-VERIFY results
CONTENTS
Online First
Early-stage Breast Cancer
Obesity is associated with worse prognosis in early-stage breast cancer
Immediate surgery can offer long-term benefits for elderly patients with early-stage breast cancer
Long-term benefit of olaparib seen in high-risk early BRCA1/2-mutated breast cancer
Active monitoring is a viable option for patients with low-risk DCIS
HER2-positive Breast Cancer
Margetuximab does not improve pCR rate in HER2-positive early breast cancer
T-DXd outperforms T-DM1 regardless of baseline genomic alterations in HER2-positive metastatic breast cancer
Encouraging results of neoadjuvant SHR-A1811 in the treatment of HER2-positive breast cancer
Additional CDK4/6 inhibition in HER2-positive patients achieves clinically meaningful outcomes
HR-positive/HER2-negative Breast Cancer
NATALEE: Success with adjuvant ribociclib leads to FDA approval in early breast cancer
Inavolisib: The first FDA-approved treatment for use in a triple combination for metastatic breast cancer
Imlunestrant monotherapy improves PFS in ESR1-mutated patients, not in the overall population
Neoadjuvant niraparib plus dostarlimab shows pCR benefit in BRCA-mutated, ER-positive/HER2-negative breast cancer
Neoadjuvant HER3-DXd achieves pCR and ORR results similar to multi-agent chemotherapy
SONIA: Potential to defer CDK4/6 inhibitor treatment without impacting HRQoL
Improved TTF and PFS seen with palbociclib plus ET in real-world PADMA study
Triple-negative Breast Cancer
KEYNOTE-522 finds prognostic value of TMB and gene profiles in TNBC
The ZEST trial sheds light on the use of ctDNA to predict breast cancer recurrence
No added EFS benefit with neoadjuvant atezolizumab in TNBC
New Insights on Radiotherapy for Breast Cancer Treatment
